Trial 0C-14-9


A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of ceralasertib in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anthony El-Khoueiry, M.D.
Other Trial Staff:  Alicia Bogardus, Coordinator, Cristina De Leon, Coordinator, Deborah Fridman, Coordinator, Victoria Amran, Coordinator, Anayansi Miloud, D.M., Xiomara Menendez, R.N., Jubilee Acap, R.N., Khatchik Karakozian, D.M., Molly Oswald, R.N., Sherine Elsayegh, Coordinator, Sodech Kim, Coordinator, Hany Ghattas, Coordinator, Atessa Kiani, Coordinator, Cristina Lee, Coordinator, Angela Smith Bryant, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.